Compare TASK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TASK | CRVS |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.5M | 843.7M |
| IPO Year | 2021 | 2016 |
| Metric | TASK | CRVS |
|---|---|---|
| Price | $8.73 | $9.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.17 | ★ $31.50 |
| AVG Volume (30 Days) | 228.6K | ★ 848.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 48.04 |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.65 | N/A |
| Revenue Next Year | $5.86 | N/A |
| P/E Ratio | $11.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.47 | $6.39 |
| 52 Week High | $12.65 | $26.95 |
| Indicator | TASK | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 39.68 |
| Support Level | $7.70 | $9.40 |
| Resistance Level | $8.83 | $10.81 |
| Average True Range (ATR) | 0.35 | 0.71 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 33.37 | 4.28 |
TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.